779 A phase I, dose escalation and expansion study of PT199, a next generation CD73 monoclonal antibody, administered alone and in combination with a PD-1 Inhibitor in adult patients with advanced solid tumors
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.